Virtual Library

Start Your Search

M. Rajer



Author of

  • +

    Poster Display session (Friday) (ID 65)

    • Event: ELCC 2018
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
    • +

      154P - CNS response to osimertinib in patients with EGFR mutated lung adenocarcinoma: Real world data (ID 524)

      12:30 - 13:00  |  Author(s): M. Rajer

      • Abstract

      Background:
      Driver mutation of epidermal frowth factor (EGFR) is presented in non-small cell lung cancer (NSCLC) at about 10%. Osimertinib (Tagrisso®) is a 3rd generation tyrosine kynase inhibitor (TKI) for EGFR mutated advanced lung adenocarcinoma with or without T790M resistant mutation. Particularly osimertinib showed a good penetration through blood-brain barrier and efficacy in central nervous system (CNS) metastases. In this, single-center, retrospective study we analyzed course of the CNS disease of metastatic NSCLC patients treated with osimertinib in any line of therapy.

      Methods:
      Patients with EGFRm advanced NSCLC who received osimertinib (80 mg daily) after progression on prior EGFR TKI (n = 23) or upfront (n = 2) were analyzed. All patients performed CT or MRI before osimertinib. We collected data on: presence of CNS metastases, line of the treatment on osimertinib, previous treatment of CNS metastases, efficacy and date of progression. Responses were evaluated radiologically every 8–16 weeks according to RECIST criteria. All patients had at least one evaluation.

      Results:
      In the present study 25 patients were included which have been treated from October 2015 untill November 2017. Among analyzed patients 10/25 (40%) had CNS (brain only) metastases before initiation with osimertinib, 4/10 received prior CNS treatment with radiotheraphy or surgery. Maximum osimertinib treatment duration was 46 /56 weeks for patients with/without CNS metastases, respectively. Median duration of treatment at the time of analysis was 27 weeks with 11/25 of patients still ongoing treatment. CNS objective response rate was 70% (CR 0%, PR 50%, SD 20%). Patients with progressive disaese (30%) had progression of all tumor leasons including CNS. There was no isolated CNS progression during osimertinib treament observed among all analyzed patients (n = 25).

      Conclusions:
      In our real world analysis osimertinib showed comparable CNS efficacy to clinical trial results with no CNS only progressive disease.

      Clinical trial identification:


      Legal entity responsible for the study:
      University Clinic Golnik

      Funding:
      Has not received any funding

      Disclosure:
      All authors have declared no conflicts of interest.